PE20010530A1 - DELAYED FORMS OF ADMINISTRATION OF TRAMADOL THROUGH A COATING CONTAINING THE ACTIVE SUBSTANCE TRAMADOL IN THE FORM OF TRAMADOL SACCHARINATE AS WELL AS OTHER EXCIPIENTS - Google Patents

DELAYED FORMS OF ADMINISTRATION OF TRAMADOL THROUGH A COATING CONTAINING THE ACTIVE SUBSTANCE TRAMADOL IN THE FORM OF TRAMADOL SACCHARINATE AS WELL AS OTHER EXCIPIENTS

Info

Publication number
PE20010530A1
PE20010530A1 PE2000000872A PE0008722000A PE20010530A1 PE 20010530 A1 PE20010530 A1 PE 20010530A1 PE 2000000872 A PE2000000872 A PE 2000000872A PE 0008722000 A PE0008722000 A PE 0008722000A PE 20010530 A1 PE20010530 A1 PE 20010530A1
Authority
PE
Peru
Prior art keywords
tramadol
administration
excipients
saccharinate
tuberable
Prior art date
Application number
PE2000000872A
Other languages
Spanish (es)
Inventor
Johannes Heinrich Antonius Bartholomaus
Iris Ziegler
Heinrich Kugelmann
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19940740A external-priority patent/DE19940740A1/en
Priority claimed from DE19940944A external-priority patent/DE19940944B4/en
Priority claimed from DE10023699A external-priority patent/DE10023699A1/en
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20010530A1 publication Critical patent/PE20010530A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA FORMA DE ADMINISTRACION DE SACARINATO DE TRAMADOL QUE TIENE AL MENOS UN REVESTIMIENTO RETARDANTE Y OTROS EXCIPIENTES SE CARACTERIZA PORQUE EL TRAMADOL ES UN COMPUESTO FORMADO IN SITU Y PARA LA PREPARACION SE UTILIZA UNA SAL HIDROSOLUBLE TOLERABLE DE TRAMADOL Y UNA SAL HIDROSOLUBLE TOLERABLE DE SACARINA; DE PREFERENCIA LA FORMA DE ADMINISTRACION SON TABLETAS, CAPSULAS, SUSPENSIONES, MULTIPLES PARTICULAS, MICROTABLETAS, MICROCAPSULAS, MICROPELLAS, GRANULADOS, CRISTALES, ENTRE OTROS, EL TAMANO DE LOS GRANULADOS O PELLAS ES DE 0,1mm A 3mm; EL REVESTIMIENTO RETARDANTE ES UN POLIMERO INSOLUBLE EN AGUA (POLIACRILATOS, POLIMETACRILATOS, ALQUILCELULOSA, ENTRE OTROS) O SINTETICO O UNA CERA NATURAL (CERA CARNAUBA, CERA DE ABEJA), GRASA, ALCOHOL GRASO; LA FORMA DE ADMINISTRACION PRESENTA UNA MATRIZ RETARDANTE QUE COMPRENDE POLIMEROS HIDROFILOS, CERAS, GRASAS; ADICIONALMENTE PRESENTA UN REVESTIMIENTO RESISTENTE A JUGO GASTRICO COMPUESTO POR POLIMEROS DE ACIDO METACRILICO, METACRILATO DE METILO; ADICIONALMENTE EL TRAMADOL SE PRESENTA EN FORMA NO RETARDADA; UTILIZANDOSE DE 10mg A 1200mg. LA FORMULACION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA INCONTINENCIA URINARIA, COMBATIR DOLORES, TOS, REACCIONES INFLAMATORIAS, ALERGICAS, DEPRESIONES, ABUSO DE DROGAS, ENFERMEDADES DE LAS VIAS RESPIRATORIAS, CARDIOVASCULARES, PSIQUICASIT REFERS TO A FORM OF ADMINISTRATION OF TRAMADOL SACCHARINATE WHICH HAS AT LEAST A RETARDANT COATING AND OTHER EXCIPIENTS IT IS CHARACTERIZED BECAUSE TRAMADOL IS A COMPOUND FORMED IN SITU AND FOR THE PREPARATION A TUBERABLE AND TUBERABLE SALT OF A SOLUBLE WATER TOLERY SALT IS USED SACCHARIN; THE PREFERRED FORM OF ADMINISTRATION ARE TABLETS, CAPSULES, SUSPENSIONS, MULTIPLE PARTICLES, MICROTABLETS, MICROCAPSULES, MICROPELLS, GRANULES, CRYSTALS, AMONG OTHERS, THE SIZE OF THE GRANULES OR PELLS IS FROM 0.1mm TO 3mm; THE RETARDANT COATING IS A WATER-INSOLUBLE POLYMER (POLYACRYLATES, POLYMETACRYLATES, ALKYLCELLULOSE, AMONG OTHERS) OR SYNTHETIC OR A NATURAL WAX (CARNAUBA WAX, BEE WAX), FAT, FATTY ALCOHOL; THE FORM OF ADMINISTRATION PRESENTS A RETARDANT MATRIX THAT INCLUDES HYDROPHILIC POLYMERS, WAXES, FATS; ADDITIONALLY IT PRESENTS A COATING RESISTANT TO GASTRIC JUICE COMPOSED OF METHACRYLIC ACID POLYMERS, METHYL METHACRYLATE; IN ADDITION THE TRAMADOL IS PRESENTED IN A NON-DELAYED FORM; USING FROM 10mg TO 1200mg. THE FORMULATION MAY BE USEFUL FOR THE TREATMENT OF URINARY INCONTINENCE, COMBAT PAIN, COUGH, INFLAMMATORY REACTIONS, ALLERGIC REACTIONS, DEPRESSIONS, DRUG ABUSE, RESPIRATORY, CARDIOVASCULAR, PSYCHIC DISEASES

PE2000000872A 1999-08-31 2000-08-25 DELAYED FORMS OF ADMINISTRATION OF TRAMADOL THROUGH A COATING CONTAINING THE ACTIVE SUBSTANCE TRAMADOL IN THE FORM OF TRAMADOL SACCHARINATE AS WELL AS OTHER EXCIPIENTS PE20010530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19940740A DE19940740A1 (en) 1999-08-31 1999-08-31 Pharmaceutical salts
DE19940944A DE19940944B4 (en) 1999-08-31 1999-08-31 Retarded, oral, pharmaceutical dosage forms
DE10023699A DE10023699A1 (en) 1999-08-31 2000-05-16 Retarded release tramadol dosage form, useful e.g. for treating pain, coughs or urinary incontinence, comprising tramadol saccharinate in retarding coating, e.g. of poly(meth)acrylate

Publications (1)

Publication Number Publication Date
PE20010530A1 true PE20010530A1 (en) 2001-06-16

Family

ID=37862697

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2000000872A PE20010530A1 (en) 1999-08-31 2000-08-25 DELAYED FORMS OF ADMINISTRATION OF TRAMADOL THROUGH A COATING CONTAINING THE ACTIVE SUBSTANCE TRAMADOL IN THE FORM OF TRAMADOL SACCHARINATE AS WELL AS OTHER EXCIPIENTS
PE2000000883A PE20010521A1 (en) 1999-08-31 2000-08-29 FORMS OF ORAL ADMINISTRATION WITH TOTAL CONTROLLED RELEASE OF ACTIVE SUBSTANCE, FINDING A SAME ACTIVE SUBSTANCE IN THE FORM OF AT LEAST TWO DIFFERENT SALTS WHICH IN THE FORM OF ADMINISTRATION ARE IN A SOLID STATE AND PRESENTING DIFE

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2000000883A PE20010521A1 (en) 1999-08-31 2000-08-29 FORMS OF ORAL ADMINISTRATION WITH TOTAL CONTROLLED RELEASE OF ACTIVE SUBSTANCE, FINDING A SAME ACTIVE SUBSTANCE IN THE FORM OF AT LEAST TWO DIFFERENT SALTS WHICH IN THE FORM OF ADMINISTRATION ARE IN A SOLID STATE AND PRESENTING DIFE

Country Status (7)

Country Link
KR (2) KR20020031419A (en)
AR (1) AR025437A1 (en)
CO (2) CO5190687A1 (en)
DE (1) DE50008261D1 (en)
HK (1) HK1047232A1 (en)
PE (2) PE20010530A1 (en)
RU (1) RU2292877C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894143B1 (en) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa PROLONGED RELEASE COMPOSITION OF THE ACTIVE INGREDIENTS, PROCESS FOR PREPARING THE SAME AND USE THEREOF

Also Published As

Publication number Publication date
RU2292877C2 (en) 2007-02-10
HK1047232A1 (en) 2003-02-14
DE50008261D1 (en) 2004-11-18
CO5190687A1 (en) 2002-08-29
AR025437A1 (en) 2002-11-27
CO5190691A1 (en) 2002-08-29
KR20020031419A (en) 2002-05-01
KR20020031421A (en) 2002-05-01
PE20010521A1 (en) 2001-06-16

Similar Documents

Publication Publication Date Title
ES2235365T3 (en) SYNERGIC ANALGESIC COMBINATION OF OPIOID ANALGESIC AND CYCLLOXYGENASA-2 INHIBITOR.
ES2203989T3 (en) SPHEROIDS, PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS.
ES2355099T3 (en) OSMOTE DEVICE WITHIN AN OSMOTE DEVICE.
ES2392396T3 (en) Osmotic diffusion / pumping drug delivery system combined
KR20040105773A (en) Compressed Tablets Comprising Microcapsules with Modified Release
PT89467B (en) PROCESS FOR THE PREPARATION OF NEW GALENIC FORMULATIONS OF PROGRAMMED LIBERTACAO
AU2011253216B2 (en) Alcohol-resistant formulations
CZ454090A3 (en) Pharmaceutical preparations for preventing and/or treating myocardial heart attack or brain apoplexy of mammals
RU2599017C2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US20090317465A1 (en) Composition and method of preparation of release systems for constant (zero-order) release of active agents
KR100895551B1 (en) Pharmaceutical Composition Comprising Lumiracoxib
Jamil et al. Review on stomach specific drug delivery systems: development and evaluation
RU2005108611A (en) TWO-Kernel Modified Release Dosage Forms
CZ70495A3 (en) Pharmaceutical form with aimed release of alfuzosin-hydrochloride
JP2011526622A5 (en)
Mondal The role of matrix tablet in drug delivery system
RU2004127237A (en) SOLID DRUG FORM WITH SLOW / CONTROLLED RELEASE AS A NEW MEDICINAL DELIVERY SYSTEM WITH A REDUCED DOSE RISK OF DOSE
MX2015001190A (en) Pharmaceutical formulation for bedwetting and method of use thereof.
PE20010530A1 (en) DELAYED FORMS OF ADMINISTRATION OF TRAMADOL THROUGH A COATING CONTAINING THE ACTIVE SUBSTANCE TRAMADOL IN THE FORM OF TRAMADOL SACCHARINATE AS WELL AS OTHER EXCIPIENTS
KR20090031011A (en) Pharmaceutical composition of artemisia extract using gastro-retentive drug delivery system and its oral sustained release formulation
EP2515880A2 (en) Novel pharmaceutical compositions of ranolazine
US20160175385A1 (en) Pharmaceutical formulation for bedwetting and method of use thereof
Bagul et al. Stomach specific drug delivery systems: a review
CN108391420A (en) Composition and its preparation method and application for reducing micturition frequency
JPH0420889B2 (en)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed